Viridian Therapeutics Operating Margin vs. Net Income
| VRDN Stock | USD 28.10 0.01 0.04% |
Viridian Therapeutics Operating Profit Margin |
|
For Viridian Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Viridian Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Viridian Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Viridian Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Viridian Therapeutics over time as well as its relative position and ranking within its peers.
Viridian Therapeutics' Revenue Breakdown by Earning Segment
Check out World Market Map.
Viridian Therapeutics Revenue Breakdown by Earning Segment
By analyzing Viridian Therapeutics' earnings estimates, investors can diagnose different trends across Viridian Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes.
Will Biotechnology sector continue expanding? Could Viridian diversify its offerings? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Viridian Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.03) | Revenue Per Share | Quarterly Revenue Growth 819.581 | Return On Assets | Return On Equity |
Understanding Viridian Therapeutics requires distinguishing between market price and book value, where the latter reflects Viridian's accounting equity. The concept of intrinsic value - what Viridian Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Viridian Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Viridian Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Viridian Therapeutics Net Income vs. Operating Margin Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Viridian Therapeutics's current stock value. Our valuation model uses many indicators to compare Viridian Therapeutics value to that of its competitors to determine the firm's financial worth. Viridian Therapeutics is rated first in operating margin category among its peers. It is rated below average in net income category among its peers . At this time, Viridian Therapeutics' Operating Profit Margin is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Viridian Therapeutics' earnings, one of the primary drivers of an investment's value.Viridian Net Income vs. Operating Margin
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Viridian Therapeutics |
| = | (0.57) % |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Viridian Therapeutics |
| = | (269.95 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Viridian Net Income Comparison
Viridian Therapeutics is currently under evaluation in net income category among its peers.
Viridian Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Viridian Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Viridian Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Viridian Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Viridian Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -11.5 K | -12.1 K | |
| Operating Income | -269.1 M | -255.7 M | |
| Income Before Tax | -243 M | -230.8 M | |
| Total Other Income Expense Net | 33.4 M | 35.1 M | |
| Net Loss | -243 M | -230.8 M | |
| Income Tax Expense | -243 M | -230.8 M | |
| Net Loss | -116.9 M | -111 M | |
| Net Interest Income | 33.4 M | 35.1 M | |
| Interest Income | 37 M | 38.8 M | |
| Net Loss | -243 M | -230.8 M | |
| Non Operating Income Net Other | 5.4 M | 5.7 M | |
| Change To Netincome | 22.7 M | 20.2 M | |
| Net Loss | (3.58) | (3.76) | |
| Income Quality | 0.77 | 0.57 | |
| Net Income Per E B T | 1.16 | 1.02 |
Viridian Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Viridian Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Viridian Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Viridian Therapeutics' important profitability drivers and their relationship over time.
Viridian Therapeutics Earnings Estimation Breakdown
The calculation of Viridian Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Viridian Therapeutics is estimated to be -1.0499 with the future projection ranging from a low of -1.1895 to a high of -0.92. Please be aware that this consensus of annual earnings estimates for Viridian Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.19 Lowest | Expected EPS | -0.92 Highest |
Viridian Therapeutics Earnings Projection Consensus
Suppose the current estimates of Viridian Therapeutics' value are higher than the current market price of the Viridian Therapeutics stock. In this case, investors may conclude that Viridian Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Viridian Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 17 | 50.0% | 0.0 | -1.0499 | -3.03 |
Viridian Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Viridian Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Viridian Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Viridian Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Viridian Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Viridian Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Viridian Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Viridian Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Viridian Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-11-05 | 2025-09-30 | -0.9532 | -0.34 | 0.6132 | 64 | ||
2025-08-06 | 2025-06-30 | -1 | -1.0 | 0.0 | 0 | ||
2025-05-06 | 2025-03-31 | -1.1 | -0.869 | 0.231 | 21 | ||
2025-02-25 | 2024-12-31 | -1.0442 | -0.81 | 0.2342 | 22 | ||
2024-11-11 | 2024-09-30 | -1.06 | -1.1546 | -0.0946 | 8 | ||
2024-08-08 | 2024-06-30 | -0.89 | -1.02 | -0.13 | 14 | ||
2024-05-08 | 2024-03-31 | -1.1 | -0.79 | 0.31 | 28 | ||
2024-02-27 | 2023-12-31 | -1 | -1.35 | -0.35 | 35 | ||
2023-11-13 | 2023-09-30 | -1.27 | -1.09 | 0.18 | 14 | ||
2023-08-08 | 2023-06-30 | -1.29 | -1.27 | 0.02 | 1 | ||
2023-05-09 | 2023-03-31 | -1.02 | -1.61 | -0.59 | 57 | ||
2023-03-08 | 2022-12-31 | -0.73 | -1.13 | -0.4 | 54 | ||
2022-11-14 | 2022-09-30 | -1.02 | -0.86 | 0.16 | 15 | ||
2022-08-15 | 2022-06-30 | -0.9 | -1.06 | -0.16 | 17 | ||
2022-05-12 | 2022-03-31 | -1.08 | -0.98 | 0.1 | 9 | ||
2022-03-10 | 2021-12-31 | -0.9 | -1.32 | -0.42 | 46 | ||
2021-11-04 | 2021-09-30 | -1.47 | -1.25 | 0.22 | 14 | ||
2021-08-11 | 2021-06-30 | -1.52 | -2.21 | -0.69 | 45 | ||
2021-05-06 | 2021-03-31 | -0.76 | -2.91 | -2.15 | 282 | ||
2021-03-25 | 2020-12-31 | -0.61 | -5.31 | -4.7 | 770 | ||
2020-11-10 | 2020-09-30 | -1.99 | -1.5 | 0.49 | 24 | ||
2020-08-05 | 2020-06-30 | -2.47 | -1.8 | 0.67 | 27 | ||
2020-05-07 | 2020-03-31 | -2.88 | -2.7 | 0.18 | 6 | ||
2020-03-11 | 2019-12-31 | -3.78 | -4.65 | -0.87 | 23 | ||
2019-11-07 | 2019-09-30 | -4.44 | -5.4 | -0.96 | 21 | ||
2019-08-07 | 2019-06-30 | -5.59 | -4.35 | 1.24 | 22 | ||
2019-05-08 | 2019-03-31 | -5.16 | -5.7 | -0.54 | 10 | ||
2019-03-13 | 2018-12-31 | -4.62 | -4.95 | -0.33 | 7 | ||
2018-11-07 | 2018-09-30 | -4.76 | -4.35 | 0.41 | 8 | ||
2018-08-07 | 2018-06-30 | -4.35 | -4.35 | 0.0 | 0 | ||
2018-05-09 | 2018-03-31 | -3.66 | -2.7 | 0.96 | 26 | ||
2018-03-14 | 2017-12-31 | -4.76 | -4.35 | 0.41 | 8 | ||
2017-11-08 | 2017-09-30 | -5.9 | -4.05 | 1.85 | 31 | ||
2017-08-11 | 2017-06-30 | -7.05 | -5.1 | 1.95 | 27 | ||
2017-05-10 | 2017-03-31 | -3.6 | -9.0 | -5.4 | 150 | ||
2017-03-24 | 2016-12-31 | -3.45 | -3.45 | 0.0 | 0 | ||
2016-08-15 | 2016-06-30 | -41.62 | -51.75 | -10.13 | 24 | ||
2016-05-16 | 2016-03-31 | -63 | -58.5 | 4.5 | 7 | ||
2016-03-16 | 2015-12-31 | -81 | -63.0 | 18.0 | 22 | ||
2015-11-12 | 2015-09-30 | -83.25 | -87.75 | -4.5 | 5 | ||
2015-08-12 | 2015-06-30 | -87.75 | -74.25 | 13.5 | 15 | ||
2015-05-14 | 2015-03-31 | -81 | -101.25 | -20.25 | 25 | ||
2015-03-30 | 2014-12-31 | -87.75 | -387.0 | -299.25 | 341 | ||
2014-11-14 | 2014-09-30 | -11.25 | -96.75 | -85.5 | 760 |
Use Viridian Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Viridian Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viridian Therapeutics will appreciate offsetting losses from the drop in the long position's value.Viridian Therapeutics Pair Trading
Viridian Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Viridian Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Viridian Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Viridian Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Viridian Therapeutics to buy it.
The correlation of Viridian Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Viridian Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Viridian Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Viridian Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Viridian Therapeutics position
In addition to having Viridian Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Semiconductor Thematic Idea Now
Semiconductor
Companies involved in production of semiconductor and semiconductor materials. The Semiconductor theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Semiconductor Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
To fully project Viridian Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Viridian Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Viridian Therapeutics' income statement, its balance sheet, and the statement of cash flows.